Recent advances in drug design of epidermal growth factor receptor inhibitors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Medicinal Chemistry

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/0929867311320160001PMID 23410174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?

  2013cited by this paper
• The critical role of vascular endothelial growth factor in tumor angiogenesis.

  2012cited by this paper
• Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.

  2012cited by this paper
• Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.

  2012cited by this paper
• Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.

  2012cited by this paper
• Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models

  2012cited by this paper
• Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review.

  2012cited by this paper
• The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers

  2012cited by this paper
• The strategic use of supramolecular pK(a) shifts to enhance the bioavailability of drugs.

  2012cited by this paper
• Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations

  2012cited by this paper
• Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer.

  2012cited by this paper
• Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.

  2011cited by this paper
• Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors.

  2011cited by this paper
• [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

  2011cited by this paper
• Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations.

  2011cited by this paper
• Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

  2011cited by this paper
• Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.

  2011cited by this paper
• Ubiquitination and downregulation of ErbB2 and estrogen receptor‐alpha by kinase inhibitor MP‐412 in human breast cancer cells

  2011cited by this paper
• Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer

  2011cited by this paper
• Tyrosine kinase inhibitors.

  2010cited by this paper
• Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

  2010cited by this paper
• Effects of epidermal growth factor receptor inhibitor‐induced dermatologic toxicities on quality of life

  2010cited by this paper
• Targeted covalent drugs of the kinase family.

  2010cited by this paper
• Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

  2010cited by this paper
• Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

  2010cited by this paper
• Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.

  2010cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

  2009cited by this paper
• ErbB receptors and signaling pathways in cancer.

  2009cited by this paper
• Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

  2009cited by this paper
• Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non–Small Cell Lung Cancer

  2009cited by this paper
• Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

  2008cited by this paper
• Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2008cited by this paper
• Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer

  2008cited by this paper
• Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

  2008cited by this paper
• EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

  2008cited by this paper
• Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer

  2008cited by this paper
• The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

  2008cited by this paper
• EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

  2008cited by this paper
• Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

  2008cited by this paper
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

  2008cited by this paper
• Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

  2008cited by this paper
• The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

  2008cited by this paper
• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

  2007cited by this paper
• The EGF receptor Hokey-Cokey.

  2007cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007cited by this paper
• Lung cancer, smoke exposure, and sex.

  2007cited by this paper
• Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

  2007cited by this paper
• A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib.

  2007cited by this paper
• Targeted drug delivery utilizing protein-like molecular architecture.

  2007cited by this paper
• EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.

  2007cited by this paper
• Pharmacological characterization of MP‐412 (AV‐412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor

  2007cited by this paper
• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

  2007cited by this paper
• Inhibition of the T790M Gatekeeper Mutant of the Epidermal Growth Factor Receptor by EXEL-7647

  2007cited by this paper
• Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

  2006cited by this paper
• Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

  2006cited by this paper
• Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.

  2006cited by this paper
• A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

  2006cited by this paper
• Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

  2006cited by this paper
• A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer

  2006cited by this paper
• Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling

  2006cited by this paper
• EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

  2005cited by this paper
• EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

  2005cited by this paper
• Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.

  2005cited by this paper
• Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.

  2005cited by this paper
• Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.

  2005cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• ErbB receptors: directing key signaling networks throughout life.

  2004cited by this paper
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

  2004cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Syntheses and EGFR kinase inhibitory activity of 6-substituted-4-anilino [1,7] and [1,8] naphthyridine-3-carbonitriles.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.

  2003cited by this paper
• Mutation of Threonine 766 in the Epidermal Growth Factor Receptor Reveals a Hotspot for Resistance Formation against Selective Tyrosine Kinase Inhibitors*

  2003cited by this paper
• Opportunities and challenges in the development of kinase inhibitor therapy for cancer.

  2003cited by this paper
• Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.

  2002cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.

  2002cited by this paper
• Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*

  2002cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

  2001cited by this paper
• Combinatorial chemoprevention of intestinal neoplasia

  2000cited by this paper
• Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.

  2000cited by this paper
• Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

  1999cited by this paper
• Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.

  1999cited by this paper

• Pyrazole derivatives as dual COX-2/EGFR inhibitors with anticancer potential: Optimization of difenamizole Analogs.

  2025cites this paper
• Benzimidazole–Pyrimidine Hybrids: Synthesis and Medicinal Properties

  2025cites this paper
• 1,3,4-Oxadiazole Based EGFR Inhibitors as Anticancer Therapeutics: SAR Study and Binding Mode of Interaction Analysis

  2025cites this paper
• A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.

  2024cites this paper
• Computational Investigations of Arylnaphthalene Lignan Lactones as Anticancer Agents

  2024cites this paper
• Recent updates on thienopyrimidine derivatives as anticancer agents

  2023cites this paper
• Tetrahydrobenzothiophene derivatives ameliorate Mia PaCa-2 cell progression and induces apoptosis via inhibiting EGFR2 tyrosine kinase signal.

  2023cites this paper
• Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations

  2023cites this paper
• Recent advances in nitrogen-containing heterocyclic compounds as receptor tyrosine kinase inhibitors for the treatment of cancer: Biological activity and structural activity relationship.

  2023cites this paper
• Identification of Activated Cdc42-Associated Kinase Inhibitors as Potential Anticancer Agents Using Pharmacoinformatic Approaches

  2023cites this paper
• Benzimidazole-linked pyrazolo[1,5-a]pyrimidine conjugates: synthesis and detail evaluation as potential anticancer agents

  2022cites this paper
• Cell Cycle Arrest and Apoptosis-Inducing Ability of Benzimidazole Derivatives: Design, Synthesis, Docking, and Biological Evaluation

  2022cites this paper
• Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives.

  2022cites this paper
• An overview on the synthetic and medicinal perspectives of indenopyrazoles.

  2019cites this paper
• Synthesis, Characterization, and Biological Activity of a Novel Series of Benzo[4,5]imidazo[2,1-b]thiazole Derivatives as Potential Epidermal Growth Factor Receptor Inhibitors

  2019cites this paper
• Design, synthesis and evaluation of novel hybrids between 4-anilinoquinazolines and substituted triazoles as potent cytotoxic agents.

  2018cites this paper
• Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R

  2017cites this paper
• Synthesis and biological evaluation of chalcone-linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents.

  2017cites this paper
• Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab

  2017cites this paper
• Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles

  2016cites this paper
• Design, synthesis, anti-tumor activity, and molecular modeling of quinazoline and pyrido[2,3-d]pyrimidine derivatives targeting epidermal growth factor receptor.

  2016cites this paper
• Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.

  2016cites this paper
• Design and Synthesis of 4‐Anilinothieno[2,3‐d]pyrimidine‐Based Compounds as Dual EGFR/HER‐2 Inhibitors

  2016cites this paper
• Virtual screening of chemical compounds active against breast cancer cell lines based on cell cycle modelling, prediction of cytotoxicity and interaction with targets$

  2015cites this paper
• Antibodies directed against receptor tyrosine kinases

  2014cites this paper
• Development of EGFR family small molecule inhibitors for anticancer intervention: an overview of approved drugs and clinical candidates.

  2014cites this paper
• Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor.

  2014cites this paper
• The first radiosynthesis of [(11)C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling.

  2014cites this paper
• Towards defining biomarkers indicating resistances to targeted therapies.

  2014cites this paper
• Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer.

  2014cites this paper
• Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.

  2014cites this paper
• Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer

  2014cites this paper